Suggested doses of Gardepanyl for specific indications are as follows:
Preoperative: 1 to 3 mg/kg.
Dosages of Gardepanyl must be individualized with full knowledge of their particular characteristics and recommended rate of administration. Factors of consideration are the patient's age, weight, and condition.
Parenteral routes should be used only when oral administration is impossible or impractical.
Anticonvulsant use: A therapeutic anticonvulsant level of Gardepanyl in serum is 10 to 25 µg/mL. To achieve the blood levels considered therapeutic in children, higher per-kilogram dosages are generally necessary for Gardepanyl and most other anticonvulsants. In children and infants, Gardepanyl at loading dose of 15 to 20 mg/kg produces blood levels of about 20 µg/mL shortly after administration.
In status epilepticus, it is imperative to achieve therapeutic blood levels of Gardepanyl as rapidly as possible. Because a barbiturate-induced depression may occur along with a postictal depression once the seizures are controlled, it is important, therefore, to use the minimal amount required, and to wait for the anticonvulsant effect to develop before administering a second dose.
Gardepanyl has been used in the treatment and prophylaxis of febrile seizures. However, it has not been established that prevention of febrile seizures influences the subsequent development of epilepsy.
Special patient population: Dosage should be reduced in the elderly or debilitated because these patients may be more sensitive to Gardepanyl. Dosage should be reduced for patients with impaired renal function or hepatic disease.
15 mg - Each white round tablet imprinted Þ 026 contains 15 mg of Gardepanyl. Tablets are supplied in bottles of 1000 (NDC 0228-2026-96).
30 mg - Each white, round, scored tablet imprinted Þ 028 contains 30 mg of Gardepanyl. Tablets are supplied in bottles of 1000 (NDC 0228-2028-96).
100 mg - Each white, round, scored tablet imprinted Þ 030 contains 100 mg of Gardepanyl. Tablets are supplied in bottles of 1000 (NDC 0228-2030-96).
Dispense in well-closed containers as defined in the USP. Store at controlled room temperature 15º- 30º C (59º- 86º F).
Red, clear elixir contains 20 mg of Gardepanyl per teaspoon (5 ml). Alcohol 13% by volume. Elixir is supplied in pints (NDC 0228-2024-16).
Preserve and dispense in tight, light- resistant containers as defined in the USP. Store at controlled room temperature 15º- 30ºC (59º- 86º F).
Before using Gardepanyl, tell your doctor if you regularly use other medicines that make you sleepy (such as other sleeping pills or seizure medicines, cold or allergy medicine, narcotic pain medicine, muscle relaxers, and medicine for depression or anxiety). They can add to sleepiness caused by Gardepanyl.
Tell your doctor about all other medicines you use, especially:
a blood thinner such as warfarin (Coumadin, Jantoven);
doxycycline (Doryx, Oracea, Periostat, Vibramycin);
other seizure medications such as divalproex (Depakote), phenytoin (Dilantin), or valproic acid (Depakene);
an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate);
griseofulvin (Grisactin, Fulvicin PG, Grifulvin V);
birth control pills or estrogen hormone replacement, including estrogen (Premarin), estradiol (Estrace, Femtrace, and others), progesterone (Progest, Prometrium), and others; or
steroids such as prednisone, dexamethasone (Decadron, Hexadrol) fluticasone (Flonase, Advair), methylprednisolone (Medrol), mometasone (Asmanex, Nasonex), and others.
This list is not complete and other drugs may interact with Gardepanyl. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Most reports of clinically significant drug interactions occurring with the barbiturates have involved Gardepanyl.
1. Anticoagulants: Gardepanyl lowers the plasma levels of dicumarol (name previously used: bishydorxycoumarin) and causes a decrease in anticoagulant activity as measured by the prothrombin time. Gardepanyl can induce hepatic microsomal enzymes resulting in increased metabolism and decreased anticoagulant response of oral anticoagulants (e.g., warfarin, acenocournarol, dicumarol, and phenprocoumon). Patients stabilized on anticoagulant therapy may require dosage adjustments if Gardepanyl is added to or withdrawn from their dosage regimen.
2. Corticosteroids: Gardepanyl appears to enhance the metabolism of exogenous corticosteroids probably through the induction of hepatic microsomal enzymes. Patients stabilized on corticosteroid therapy may require dosage adjustments if Gardepanyl is added to or withdrawn from their dosage regimen.
3. Griseofulvin: Gardepanyl appears to interfere with the absorption of orally administered griseofulvin, thus decreasing its blood level. The effect of the resultant decreased blood levels of griseofulvin on therapeutic response has not been established. However, it would be preferable to avoid concomitant administration of these drugs.
4. Doxycycline: Gardepanyl has been shown to shorten the half- life of doxycycline for as long as 2 weeks after barbiturate therapy is discontinued. This mechanism is probably through the induction of hepatic microsomal enzymes that metabolize the antibiotic. If Gardepanyl and doxycycline are administered concurrently, the clinical response to doxycycline should be monitored closely.
5. Phenytoin, sodium valproate, valproic acid: The effect of Gardepanyl on the metabolism of phenytoin appears to be variable. Some investigators report an accelerating effect, while others report no effect. Because the effect of Gardepanyl on the metabolism of phenytoin is not predictable, phenytoin and Gardepanyl blood levels should be monitored more frequently if these drugs are given concurrently. Sodium valproate and valproic acid appear to decrease Gardepanyl metabolism; therefore, Gardepanyl blood levels should be monitored and appropriate dosage adjustments made as indicated.
6. Central nervous system depressants: The concomitant use of other central nervous system depressants including other sedatives or hypnotics, antihistamines, tranquilizers, or alcohol, may produce additive depressant effects.
7. Monoamine oxidase inhibitors (MAOIs): MAOIs prolong the effects of Gardepanyl probably because metabolism of the Gardepanyl is inhibited.
8. Estradiol, estrone, progesterone and other steroidal hormones: Pretreatment with or concurrent administration of Gardepanyl may decrease the effect of estradiol by increasing its metabolism. There have been reports of patients treated with antiepileptic drugs (e.g., Gardepanyl) who became pregnant while taking oral contraceptives. An alternate contraceptive method might be suggested to women taking Gardepanyl.
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology